Efficacy of an Immune Modulator in Experimental Chlamydia trachomatis Infection of the Female Genital Tract
Authors:
Open Access
- 1 January 2006
- journal article
- research article
- Published by Wiley in Infectious Diseases in Obstetrics and Gynecology
- Vol. 2006 (1) , 61265
Abstract
Objective. The aim of this study was to determine if vaginal application of the immune response modifier imiquimod (Aldara cream, 3M Pharmaceuticals, St Paul, Minn) would alter the course and/or outcome of female genital tract infection with a human isolate of Chlamydia trachomatis in a murine model. Methods. Groups of CF-1 mice were treated with Aldara on three different schedules: (1) ongoing beginning 5 days prior to and continuing through day 5 of infection; (2) a single prophylactic dose 2 hours prior to infection; and (3) therapeutic from day 4 to day 14 of infection. Mice were infected vaginally with a serovar D strain of C trachomatis, and monitored by culture to determine the level of shedding and duration of infection. Results. We observed a significant reduction in both duration of infection and the level of shedding during the acute phase in mice treated on an ongoing basis commencing 5 days prior to infection. There was no effect with respect to the other regimens. Conclusion. These results demonstrate that ongoing Aldara treatment has efficacy and may enhance local innate immunity which reduces the duration of subsequent infection with human isolates of C trachomatis in a murine model of female genital tract infection.Keywords
Funding Information
- Tramedico BV, The Netherlands
- Falk Foundation
- VU University Medical Center
- Foundation of Immunogenetics
This publication has 43 references indexed in Scilit:
- Differences in growth characteristics and elementary body associated cytotoxicity between Chlamydia trachomatis oculogenital serovars D and H and Chlamydia muridarumJournal of Clinical Pathology, 2005
- Imiquimod as a dermatological therapyExpert Opinion on Pharmacotherapy, 2004
- The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamilyEuropean Journal of Immunology, 2003
- Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled StudyAntimicrobial Agents and Chemotherapy, 2002
- Successful Treatment of Drug‐Resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an ImmunomodulatorClinical Infectious Diseases, 2001
- Treatment of Experimental Leishmaniasis with the Immunomodulators Imiquimod and S‐28463: Efficacy and Mode of ActionThe Journal of Infectious Diseases, 1999
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- Pelvic Inflammatory Disease and FertilitySexually Transmitted Diseases, 1992
- Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effectsCellular and Molecular Life Sciences, 1989
- Progesterone as a key factor in the development of a mouse model for genital-tract infection withChlamydia trachomatisFEMS Microbiology Letters, 1981